Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp
The aim of this study was to investigate the effect of two different glucose levels on GH response to the combined administration of GHRH+GHRP-6 in patients with type 2 diabetes. GH response to i.v. bolus of GHRH+GHRP-6 (100 mcg, each) was measured in 12 male patients with type 2 diabetes (mean age:...
Gespeichert in:
| Veröffentlicht in: | Diabetes research and clinical practice 2004, Vol.63 (1), p.37-45 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 45 |
|---|---|
| container_issue | 1 |
| container_start_page | 37 |
| container_title | Diabetes research and clinical practice |
| container_volume | 63 |
| creator | Micic, Dragan Kendereski, Aleksandra Sumarac-Dumanovic, Mirjana Cvijovic, Goran Popovic, Vera Dieguez, Carlos Casanueva, Felipe |
| description | The aim of this study was to investigate the effect of two different glucose levels on GH response to the combined administration of GHRH+GHRP-6 in patients with type 2 diabetes. GH response to i.v. bolus of GHRH+GHRP-6 (100
mcg, each) was measured in 12 male patients with type 2 diabetes (mean age: 53.9±1.59 years; BMI: 25.58±0.39
kg/m
2; mean HbA
1c: 8.7±0.42%), during a euglycemic (mean glucose: 4.92±0.08
mmol) hyperinsulinemic clamp (insulin infusion rate of 100
mU/kg/h) and a hyperglycemic clamp (mean glucose: 12.19±0.11
mmol/l). There was no difference in basal GH levels between the hyperglycemic and euglycemic clamps (2.9±0.99
mU/l versus 1.48±0.44
mU/l;
P>0.05). Peak GH response to GHRH+GHRP-6 during the hyperglycemic clamp was lower than in the englycemic clamp (112.45±14.45
mU/l versus 151.06±16.87
mU/l;
P |
| doi_str_mv | 10.1016/j.diabres.2003.08.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80070029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016882270300216X</els_id><sourcerecordid>80070029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c276t-a48f83b7ff47102aefd3028a30ec4d1250240f683c939ebf84af4d81af6d55c43</originalsourceid><addsrcrecordid>eNqFkE1r3DAQhkVoSbZpf0KCTr0UO6MP29pTCKHdLQQSQnIWWmmU1WJbrmS37L-vt7u0x55mGJ6Zl3kIuWJQMmD1za50wWwS5pIDiBJUCYyfkQVTDS8U5807spg59ae_IB9y3gFALWR1Ti6YrJdCMrYguErx17il25i62COdDw6xz0jHSFfr5zX9cihPRU1DT8f9gJTTQzCOmKmbUujfKE5v7d5iFyw1vaPbmUp_J7Y13fCRvPemzfjpVC_J67evL_fr4uFx9f3-7qGwvKnHwkjlldg03suGATfonQCujAC00jFeAZfgayXsUixx45U0XjrFjK9dVVkpLsnn490hxR8T5lF3IVtsW9NjnLJWAA0AX85gdQRtijkn9HpIoTNprxnog1-90ye_-uBXg9Kz33nv-hQwbTp0_7ZOQmfg9gjg_ObPgElnG7C36EJCO2oXw38ifgPqwY4Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80070029</pqid></control><display><type>article</type><title>Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Micic, Dragan ; Kendereski, Aleksandra ; Sumarac-Dumanovic, Mirjana ; Cvijovic, Goran ; Popovic, Vera ; Dieguez, Carlos ; Casanueva, Felipe</creator><creatorcontrib>Micic, Dragan ; Kendereski, Aleksandra ; Sumarac-Dumanovic, Mirjana ; Cvijovic, Goran ; Popovic, Vera ; Dieguez, Carlos ; Casanueva, Felipe</creatorcontrib><description>The aim of this study was to investigate the effect of two different glucose levels on GH response to the combined administration of GHRH+GHRP-6 in patients with type 2 diabetes. GH response to i.v. bolus of GHRH+GHRP-6 (100
mcg, each) was measured in 12 male patients with type 2 diabetes (mean age: 53.9±1.59 years; BMI: 25.58±0.39
kg/m
2; mean HbA
1c: 8.7±0.42%), during a euglycemic (mean glucose: 4.92±0.08
mmol) hyperinsulinemic clamp (insulin infusion rate of 100
mU/kg/h) and a hyperglycemic clamp (mean glucose: 12.19±0.11
mmol/l). There was no difference in basal GH levels between the hyperglycemic and euglycemic clamps (2.9±0.99
mU/l versus 1.48±0.44
mU/l;
P>0.05). Peak GH response to GHRH+GHRP-6 during the hyperglycemic clamp was lower than in the englycemic clamp (112.45±14.45
mU/l versus 151.06±16.87
mU/l;
P<0.05). Area under the GH curve was lower in the hyperglycemic than in the euglycemic clamp (6974.49±1001.95
mU/l/min versus 9560.75±1140.65
mU/l/min;
P<0.05). It is concluded that hyperglycemia significantly reduces GH response to combined administration of GHRH+GHRP-6 in normal weight patients with type 2 diabetes. It is suggested that ambient glucose levels should be taken into account during interpretation of GH response to combined administration of GHRH+GHRP-6 in patients with type 2 diabetes.</description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2003.08.012</identifier><identifier>PMID: 14693411</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - metabolism ; Drug Combinations ; Euglycemic clamp ; GHRH + GHRP-6 ; Glucose Clamp Technique ; Growth hormone ; Growth Hormone-Releasing Hormone - administration & dosage ; Human Growth Hormone - blood ; Human Growth Hormone - metabolism ; Humans ; Hyperglycemia - metabolism ; Hyperglycemic clamp ; Hyperinsulinism - metabolism ; Injections, Intravenous ; Insulin - blood ; Male ; Middle Aged ; Oligopeptides - administration & dosage ; Reproducibility of Results ; Type 2 diabetes</subject><ispartof>Diabetes research and clinical practice, 2004, Vol.63 (1), p.37-45</ispartof><rights>2003 Elsevier Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c276t-a48f83b7ff47102aefd3028a30ec4d1250240f683c939ebf84af4d81af6d55c43</citedby><cites>FETCH-LOGICAL-c276t-a48f83b7ff47102aefd3028a30ec4d1250240f683c939ebf84af4d81af6d55c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S016882270300216X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,4009,27902,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14693411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Micic, Dragan</creatorcontrib><creatorcontrib>Kendereski, Aleksandra</creatorcontrib><creatorcontrib>Sumarac-Dumanovic, Mirjana</creatorcontrib><creatorcontrib>Cvijovic, Goran</creatorcontrib><creatorcontrib>Popovic, Vera</creatorcontrib><creatorcontrib>Dieguez, Carlos</creatorcontrib><creatorcontrib>Casanueva, Felipe</creatorcontrib><title>Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description>The aim of this study was to investigate the effect of two different glucose levels on GH response to the combined administration of GHRH+GHRP-6 in patients with type 2 diabetes. GH response to i.v. bolus of GHRH+GHRP-6 (100
mcg, each) was measured in 12 male patients with type 2 diabetes (mean age: 53.9±1.59 years; BMI: 25.58±0.39
kg/m
2; mean HbA
1c: 8.7±0.42%), during a euglycemic (mean glucose: 4.92±0.08
mmol) hyperinsulinemic clamp (insulin infusion rate of 100
mU/kg/h) and a hyperglycemic clamp (mean glucose: 12.19±0.11
mmol/l). There was no difference in basal GH levels between the hyperglycemic and euglycemic clamps (2.9±0.99
mU/l versus 1.48±0.44
mU/l;
P>0.05). Peak GH response to GHRH+GHRP-6 during the hyperglycemic clamp was lower than in the englycemic clamp (112.45±14.45
mU/l versus 151.06±16.87
mU/l;
P<0.05). Area under the GH curve was lower in the hyperglycemic than in the euglycemic clamp (6974.49±1001.95
mU/l/min versus 9560.75±1140.65
mU/l/min;
P<0.05). It is concluded that hyperglycemia significantly reduces GH response to combined administration of GHRH+GHRP-6 in normal weight patients with type 2 diabetes. It is suggested that ambient glucose levels should be taken into account during interpretation of GH response to combined administration of GHRH+GHRP-6 in patients with type 2 diabetes.</description><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Drug Combinations</subject><subject>Euglycemic clamp</subject><subject>GHRH + GHRP-6</subject><subject>Glucose Clamp Technique</subject><subject>Growth hormone</subject><subject>Growth Hormone-Releasing Hormone - administration & dosage</subject><subject>Human Growth Hormone - blood</subject><subject>Human Growth Hormone - metabolism</subject><subject>Humans</subject><subject>Hyperglycemia - metabolism</subject><subject>Hyperglycemic clamp</subject><subject>Hyperinsulinism - metabolism</subject><subject>Injections, Intravenous</subject><subject>Insulin - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oligopeptides - administration & dosage</subject><subject>Reproducibility of Results</subject><subject>Type 2 diabetes</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1r3DAQhkVoSbZpf0KCTr0UO6MP29pTCKHdLQQSQnIWWmmU1WJbrmS37L-vt7u0x55mGJ6Zl3kIuWJQMmD1za50wWwS5pIDiBJUCYyfkQVTDS8U5807spg59ae_IB9y3gFALWR1Ti6YrJdCMrYguErx17il25i62COdDw6xz0jHSFfr5zX9cihPRU1DT8f9gJTTQzCOmKmbUujfKE5v7d5iFyw1vaPbmUp_J7Y13fCRvPemzfjpVC_J67evL_fr4uFx9f3-7qGwvKnHwkjlldg03suGATfonQCujAC00jFeAZfgayXsUixx45U0XjrFjK9dVVkpLsnn490hxR8T5lF3IVtsW9NjnLJWAA0AX85gdQRtijkn9HpIoTNprxnog1-90ye_-uBXg9Kz33nv-hQwbTp0_7ZOQmfg9gjg_ObPgElnG7C36EJCO2oXw38ifgPqwY4Q</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>Micic, Dragan</creator><creator>Kendereski, Aleksandra</creator><creator>Sumarac-Dumanovic, Mirjana</creator><creator>Cvijovic, Goran</creator><creator>Popovic, Vera</creator><creator>Dieguez, Carlos</creator><creator>Casanueva, Felipe</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2004</creationdate><title>Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp</title><author>Micic, Dragan ; Kendereski, Aleksandra ; Sumarac-Dumanovic, Mirjana ; Cvijovic, Goran ; Popovic, Vera ; Dieguez, Carlos ; Casanueva, Felipe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c276t-a48f83b7ff47102aefd3028a30ec4d1250240f683c939ebf84af4d81af6d55c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Drug Combinations</topic><topic>Euglycemic clamp</topic><topic>GHRH + GHRP-6</topic><topic>Glucose Clamp Technique</topic><topic>Growth hormone</topic><topic>Growth Hormone-Releasing Hormone - administration & dosage</topic><topic>Human Growth Hormone - blood</topic><topic>Human Growth Hormone - metabolism</topic><topic>Humans</topic><topic>Hyperglycemia - metabolism</topic><topic>Hyperglycemic clamp</topic><topic>Hyperinsulinism - metabolism</topic><topic>Injections, Intravenous</topic><topic>Insulin - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oligopeptides - administration & dosage</topic><topic>Reproducibility of Results</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Micic, Dragan</creatorcontrib><creatorcontrib>Kendereski, Aleksandra</creatorcontrib><creatorcontrib>Sumarac-Dumanovic, Mirjana</creatorcontrib><creatorcontrib>Cvijovic, Goran</creatorcontrib><creatorcontrib>Popovic, Vera</creatorcontrib><creatorcontrib>Dieguez, Carlos</creatorcontrib><creatorcontrib>Casanueva, Felipe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Micic, Dragan</au><au>Kendereski, Aleksandra</au><au>Sumarac-Dumanovic, Mirjana</au><au>Cvijovic, Goran</au><au>Popovic, Vera</au><au>Dieguez, Carlos</au><au>Casanueva, Felipe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2004</date><risdate>2004</risdate><volume>63</volume><issue>1</issue><spage>37</spage><epage>45</epage><pages>37-45</pages><issn>0168-8227</issn><eissn>1872-8227</eissn><abstract>The aim of this study was to investigate the effect of two different glucose levels on GH response to the combined administration of GHRH+GHRP-6 in patients with type 2 diabetes. GH response to i.v. bolus of GHRH+GHRP-6 (100
mcg, each) was measured in 12 male patients with type 2 diabetes (mean age: 53.9±1.59 years; BMI: 25.58±0.39
kg/m
2; mean HbA
1c: 8.7±0.42%), during a euglycemic (mean glucose: 4.92±0.08
mmol) hyperinsulinemic clamp (insulin infusion rate of 100
mU/kg/h) and a hyperglycemic clamp (mean glucose: 12.19±0.11
mmol/l). There was no difference in basal GH levels between the hyperglycemic and euglycemic clamps (2.9±0.99
mU/l versus 1.48±0.44
mU/l;
P>0.05). Peak GH response to GHRH+GHRP-6 during the hyperglycemic clamp was lower than in the englycemic clamp (112.45±14.45
mU/l versus 151.06±16.87
mU/l;
P<0.05). Area under the GH curve was lower in the hyperglycemic than in the euglycemic clamp (6974.49±1001.95
mU/l/min versus 9560.75±1140.65
mU/l/min;
P<0.05). It is concluded that hyperglycemia significantly reduces GH response to combined administration of GHRH+GHRP-6 in normal weight patients with type 2 diabetes. It is suggested that ambient glucose levels should be taken into account during interpretation of GH response to combined administration of GHRH+GHRP-6 in patients with type 2 diabetes.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>14693411</pmid><doi>10.1016/j.diabres.2003.08.012</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 2004, Vol.63 (1), p.37-45 |
| issn | 0168-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80070029 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - metabolism Drug Combinations Euglycemic clamp GHRH + GHRP-6 Glucose Clamp Technique Growth hormone Growth Hormone-Releasing Hormone - administration & dosage Human Growth Hormone - blood Human Growth Hormone - metabolism Humans Hyperglycemia - metabolism Hyperglycemic clamp Hyperinsulinism - metabolism Injections, Intravenous Insulin - blood Male Middle Aged Oligopeptides - administration & dosage Reproducibility of Results Type 2 diabetes |
| title | Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T14%3A59%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Growth%20hormone%20response%20to%20GHRH%20+%20GHRP-6%20in%20type%202%20diabetes%20during%20euglycemic%20and%20hyperglycemic%20clamp&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Micic,%20Dragan&rft.date=2004&rft.volume=63&rft.issue=1&rft.spage=37&rft.epage=45&rft.pages=37-45&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2003.08.012&rft_dat=%3Cproquest_cross%3E80070029%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80070029&rft_id=info:pmid/14693411&rft_els_id=S016882270300216X&rfr_iscdi=true |